Dierential display PCR [DD-PCR] was applied to identify mRNAs dierentially expressed between two consecutive stages of an in vivo model of mouse mammary carcinogenesis. The extended life 12 [EL12] and transformed mammary 12 [TM12] outgrowths dier in morphology, ovarian hormone dependence, and tumorigenicity, yet the TM12 outgrowth arose spontaneously from the EL12 outgrowth. A fragment of the mouse p96 gene was identi®ed using DD-PCR. The dierential expression of p96 was con®rmed using RNase protection assays. Examination of the RNA expression patterns of the p96 isoforms during normal mammary gland development showed high levels in the involuting mammary gland and in preneoplastic hyperplasias. In contrast, p96 isoform mRNA levels were consistently decreased in mammary tumors derived from the in vivo hyperplasias. Examination of p96 protein levels revealed a decrease in p96 protein in a number of mammary tumors as compared to their hyperplastic precursors further supporting the observations that p96 gene expression is consistently downregulated in mammary tumors. The functional activity of p96 protein has not been resolved, however the observation that p96 gene expression is downregulated in two dierent tumor systems (human ovarian tumors and mouse mammary tumors) warrants more extensive investigation on its role in normal and neoplastic cell growth.
Introduction
The EL-TM set of mouse mammary ductal and alveolar outgrowth lines in vivo is a useful model for examination of multistage mammary tumorigenesis. The outgrowth lines were derived by culturing virgin mammary epithelial cells in a collagen gel culture followed by serially passaging the cells in a monolayer culture. The cultured cells were then transplanted into the cleared mammary fat pads of syngeneic mice to generate mammary outgrowths. The mammary outgrowths were characterized by serial transplantation and segregated into three groups (Medina and Kittrell, 1993; Medina et al., 1993a) . The vast majority were ductal outgrowths and had a ®nite proliferation potential. However, at least four outgrowths surpassed their life expectancy of four to ®ve transplant generations. These outgrowths were named`EL' for extended life'. One of these outgrowths, EL12, has been serially transplanted for 8 yrs. The histomorphology of EL12 outgrowth is primarily ductal with some alveolar dierentiation. The EL12 outgrowth is ovarian hormone-dependent and produces tumors at the low frequency and long tumor latency period (13% of the transplants with tumors appearing at 510 months). At the 16th transplant generation it was noticed that several of the EL12 outgrowths were predominantly alveolar. This subset of outgrowths was separately transplanted and has been maintained as a stable alveolar outgrowth, designated`TM12' for`transformed mammary'. Further experiments determined that TM12 is indeed distinct from EL12, because it is no longer ovarian hormone-dependent and produces tumors at a higher frequency (70% of the transplants with a 50% tumor endpoint of 9.5 months). The spontaneous development of TM12 outgrowths from the EL12 outgrowths provided a unique system in which to study dierential gene expression related to the acquisition of the hyperplastic and neoplastic phenotypes. The third group of outgrowths established by this in vitro-in vivo protocol was the alveolar outgrowths, designated TM, which were stable and immortal populations with various tumor-producing capabilities (Medina et al., 1993a) .
p96 is a mitogen-responsive phosphoprotein recently cloned from a mouse macrophage cell expression library (Xu et al., 1995) . The cDNA was isolated based on a search for proteins with regions of homology with extracellular signal-regulated kinase 1 (ERK1). A portion of the human homolog of p96, DOC-2, was initially isolated by RNA-based arbitrarily primed PCR [RAP] as a message downregulated in ovarian carcinomas as compared to normal ovarian surface epithelium (Mok et al., 1994) . DOC-2 expression was detected by RAP at relatively high levels in three normal human ovarian surface epithelial cell cultures and one normal human ovary, and at lower levels in nine ovarian carcinoma cell lines and 14 Stage III/IV ovarian serous cystadenocarcinomas. In situ hybridization with a DOC-2 riboprobe identi®ed the ovarian surface epithelium as the most brightlystaining region of the ovary. The full-length cDNA for the human homolog of p96, DOC-2, was recently cloned and mapped to chromosome 5p13 (Albertsen et al., 1996) . p96 can be alternatively spliced (Xu et al., 1995) to produce three isoforms which migrate on polyacrylamide gels as p96, p93 and p67. Endogenous p96 in mouse macrophages (BAC1.2F5 cells) is phosphorylated on serine residues after treatment with colonystimulating factor-1 (CSF-1) (Xu et al., 1995) . This result suggests that p96 may be involved in transducing the CSF-1 signal to the mitogen-activated protein (MAP) kinase pathway. CSF-1 is a growth factor that is required for the G1-to-S transition of the cell cycle in both macrophages (Tushinski and Stanley, 1985) and myoblasts (Borycki et al., 1995) . Interestingly, an inactivating mutation of the CSF-1 gene leads to the osteopetrotic phenotype (op/op) (WiktorJedrezejczak et al., 1990) . Osteopetrotic mice exhibit abnormal mammary gland growth, improper differentiation during pregnancy, and the inability to nurse a full litter (Pollard and Hennighausen, 1994) . Lewis lung cancer cells, when transplanted into osteopetrotic mice, exhibit markedly impaired tumor growth as compared to transplants into normal littermates, implying that CSF-1 may be necessary for tumor formation and metastasis (Nowicki et al., 1996) . These reports taken together suggest that CSF-1 plays an important role in many cell types, including the mammary gland, and may be involved in tumorigenesis. It was therefore interesting that a protein, p96, phosphorylated within 2 min of CSF-1 treatment of macrophages, was recently isolated in our laboratory as a gene downregulated in transplantable outgrowths and tumors in the mouse mammary gland.
Results
The original dierential display PCR identi®ed a cDNA, designated k-1, of approximately 274 nucleotides that was downregulated consistently in TM12 outgrowths when compared to EL12 outgrowths (Figures 1 and 2 ). The cloning of this PCR product into the pGEM-T vector and subsequent dot blot analysis proved that the cloned product was present in the greatest quantity, as previous reports have indicated that dierential display PCR bands may contain two to four individual cDNAs (Callard et al., 1994) . Sequence analysis and comparison identi®ed this clone as a 3' portion of the recently cloned mouse p96 cDNA. This clone, termed k-1, was 98.8% identical between nucleotides 3090 and 3340 of the mouse p96 sequence. The dierential expression of p96 was con®rmed in several independent RNase protection assays (Figure 2 ). b-actin levels were used as internal standards. The extent of p96 downregulation between EL12 and TM12 outgrowth averaged 77.8% in ®ve independent experiments (Figures 2 and 3).
The results reported by Xu et al. (1995) indicated that there were three potential isoforms of this gene: p96, p93 and p67. RT ± PCR was used to examine the expression of each isoform in a large set of normal, hyperplastic and neoplastic mammary tissues. These experiments determined that the p96 and the p67 isoforms of p96 are expressed in all mammary tissues examined (data not shown). The p93 message was not detected, a result similar to that found by Xu et al. (1995) . The ratio of the p96 : p67 isoforms did not change signi®cantly during normal mammary gland development or tumorigenesis.
RNase protection assays were used to study the levels of the p96 and p67 isoforms of p96 in dierent in vivo mammary gland tissues, hyperplastic outgrowths and tumors. The p96 isoform was expressed in all mammary tissues examined, including virgin, midpreg- Figure 1 Dierential display PCR of the EL12 and TM12 outgrowths. Arrows indicate mRNAs that are potentially dierentially expressed. k-1 was sequenced and found to be a 3' untranslated region of mouse p96. Samples were handled in triplicate and experiments were repeated to ensure that bands were dierentially expressed. A 32 P-labeled ladder was run for approximate size estimation. EL12 and TM12 samples are separated by a well which contained some spill-over from the EL12 sample. The third TM12 sample represents a PCR which did not amplify eciently , as well as in normal mouse tissues such as lung, liver, spleen, gut, kidney, brain, ovary and testis (data not shown). Importantly, p96 mRNA levels were decreased in a number of tumors when compared to their respective precursor hyperplasias (Figure 3 ). Decreased expression of the p96 and p67 isoforms of p96 was observed for tumors derived from the EL12, TM2L, TM2H, TM10, TM3, TM40A and TM40C hyperplasias ( Figure 3 and data not shown). The mRNA isoform levels were quantitated by densitometry and normalized to the b-actin signal. A 70% decline was found for seven sets of tumors when compared to their precursor hyperplasias (Figure 4 ), in addition to the downregulation originally detected in the EL12-TM12 comparison. Interestingly, there was no further decrease of p96 message in TM12 tumors compared to TM12 hyperplasias, suggesting that p96 downregulation could be an early step in mammary tumorigenesis. The quantitative data presented here for p96 downregulation in mouse mammary tumors, in combination with the report that the human homolog, DOC-2, is downregulated in ovarian carcinomas as compared to normal ovarian surface epithelium (Mok et al., 1994) , suggest that expression of p96 may be a frequent event in tumorigenesis. Immunoblot analysis of protein samples from the hyperplasia/tumor sets examined in Figure 3 showed that p96 protein is downregulated in the tumors of ®ve of the seven hyperplasia/tumor sets that demonstrated downregulation of p96 mRNA levels ( Figure 5 ). Protein levels were decreased in tumors derived from the following hyperplasias: EL12, TM2L, TM2H, TM10 and TM40A (data not shown). The p96 protein levels were already at low levels in the TM3 and TM40C hyperplastic outgrowths. Reprobing of the immunoblot with an anti-actin antibody showed that the TM3 hyperplasia sample was underloaded with respect to the TM3 tumor sample. The downregulation of p96 protein levels in several mammary tumors further supports the signi®cance of the decreased mRNA expression.
RNase protection assays were also used to delineate the pattern of p96 isoform message expression during normal mammary gland development (Figure 3) . The highest levels were found in the involuted mammary gland, suggesting that p96 may be more highly expressed in cell populations that had experienced substantial apoptosis. The midpregnant mammary gland expressed the lowest levels of total p96: virgin mammary gland levels were elevated 1.7-fold; lactating mammary gland levels were elevated 1.9-fold; and the involuted mammary gland showed the highest levels of p96 expression at 2.7-fold above levels seen in the midpregnant mammary gland. This observation suggests that p96 may be a gene whose product is involved in the terminal dierentiation of the mammary gland, and may therefore be involved in the well-demonstrated breast cancer protective eects of pregnancy and parturition.
Discussion
The data presented here demonstrate that p96 mRNA expression is consistently downregulated in murine mammary tumors. One possible function for p96 may and DMBA-induced tumors (DMBA) were hybridized with a mixture of in vitro-transcribed p96-speci®c, p67-speci®c, and bactin probed, digested, and run on a polyacrylamide gel as described. Endogenous levels of b-actin were used for normalizing samples. Virgin, midpregnant, lactating and involuted mammary samples have been repeated twice; all other samples have been repeated once. The EL12 and TM12 samples have been repeated more than ®ve times Figure 4 p96 expression is downregulated in mammary tumors when compared to their corresponding hyperplasias. RNase protection assay results for the p96 and p67 probes were scanned densitometrically, normalized to endogenous b-actin levels in the midpregnant mammary gland levels, and added together to obtain relative total p96 amounts. The average decrease of total p96 was 69.7%; the standard error of the mean was 5.14%. Samples TM40A-O, TM40A-T, TM40C-O and TM40C-T were repeated once; all other tissues were repeated twice Figure 5 p96 protein levels are decreased in mouse mammary tumors as compared to their corresponding hyperplasias. 500 mg of protein lysate was electrophoresed through a 7.5% acrylamide gel as described. After ECL detection, the membrane was stripped and reprobed with an anti-actin antibody to ensure equal loading be tumor suppression. This idea is supported by the results of studies on human ovarian cancer where it was demonstrated that DOC-2, the human homolog of p96, was downregulated when compared to normal ovarian surface epithelium (Mok et al., 1994) . To date, there are only four publications on this gene or its human homolog, thus information on the regulation, distribution and function of this gene and its product are meager. However, it is interesting and provocative that two of four papers (including this report) demonstrate that p96 is a gene whose expression is downregulated in tumors. The consistency of the results as evidenced by the 70% decrease in RNA expression in seven independent sets of mammary hyperplasias and neoplasias suggests that the downregulation may be important for neoplastic growth. These tumors have also been examined for p53, RB and ras expression. These genes showed no or inconsistent changes in gene expression or mutation depending on the outgrowth line. The only other putative tumor suppressor gene whose expression is consistently downregulated in these lesions is gelsolin (Medina et al., 1993b) , a gene whose protein is involved in actin micro®lament polymerization dynamics. Future studies will test the tumor suppressor potential of p96 by transfecting the full-length p96 cDNA into a mouse mammary tumor cell line, obtaining a stable p96-overexpressing line, and examining the growth potential of the transfectants under in vitro and in vivo conditions.
As indicated above, the function of p96 is still unknown; however, analysis of the amino acid sequence identi®es several well-characterized functional domains. A four-amino acid motif is shared with the actin-binding molecule villin (Friedrich et al., 1992) , suggesting that p96 may bind the cytoskeleton. To date, one other signal transduction protein, p130 Cas , which helps couple ras to the MAP kinase pathway, has been shown to bind the cytoskeleton (Sakai et al., 1994) . p96 contains the phosphotyrosine binding (PTB) domain (Kavanaugh and Williams, 1994) , which implies that it may interact with receptor tyrosine kinases, as does shc. This signal transduction molecule, which also contains a PID, binds both the epidermal growth factor [EGF] receptor and the nerve growth factor receptor (Dikic et al., 1995) . p96 may also interact with SH3-domaincontaining proteins, as do many proline-rich signal transduction proteins. The proline-rich domains of both sos and p120 cbl bind the SH3 domain of the adaptor Grb2 (Egan et al., 1993; Donovan et al., 1994) . Similarly, the proline-rich region of Sin binds both Src and Crk (Alexandropoulos and Baltimore, 1996) .
Analysis of the available information suggests that this protein could function in the signal transduction pathway that leads from growth factors such as CSF-1 (and potentially EGF) (Jackowski et al., 1997) to the GTP exchange factor sos and the MAP kinase cascade. This argument is supported by the recognition of a potential cytoskeletal involvement region, SH3-binding domains, and the phosphotyrosine interaction domain in the deduced amino acid sequence of p96.
In summary, p96 is a newly described gene whose expression is downregulated in human ovarian carcinoma and mouse mammary tumors and has all the structural characteristics of a growth factorstimulated protein active in signal transduction. Additional experiments are needed to determine the potential and function of this gene in tumorigenesis.
Materials and methods

Serial transplantation of mammary gland tissues
All normal, hyperplastic and neoplastic mammary tissues were of Balb/c origin. The tissues representative of dierent stages of mouse mammary tumorigenesis were serially transplanted and maintained as described (Medina and Kittrell, 1993; Medina et al., 1993a) . The EL and TM outgrowth lines were originally derived from cell cultures of normal adult virgin mammary gland. At early passages (p2-p11), the cells were injected into the cleared mammary fat pads of syngeneic BALB/c mice. The resulting outgrowths were serially passaged every 8 ± 12 weeks. The EL outgrowths are ductal and possess low tumorigenic potential; however, chemical carcinogens such as 7,12-dimethylbenzanthracene (DMBA) can readily induce tumor formation in the EL12 outgrowth line. The TM outgrowths are alveolar and possess various tumor potentials. Tumors develop from their respective preneoplastic hyperplasias in a stochastic manner and were collected as they arose in the host. The EL ductal and TM alveolar outgrowths were collected after the transplants had ®lled the fat pad (412 weeks post transplantation), frozen in liquid nitrogen, and stored at 7808C until utilized for analysis. The tumors were collected when they were 10 ± 15 mm in largest dimension. The original dierential display PCR compared total RNA pooled from ®ve fat pads containing EL12 ductal outgrowths and four fat pads containing TM12 alveolar outgrowths.
Removal of DNA from RNA samples and reverse-transcription-PCR
Total RNA was extracted and puri®ed from both subcon¯uent cell cultures and tissues using modi®cations of the guanidium thiocyanate method (Chomczynski and Sacchi, 1987) . The RNazol B (Biotecx Laboratories) method was used. RNA pellets were resuspended in diethyl pyrocarbonate (DEPC)-treated ddH 2 O. RNA was considered to be pure if the ratio of A 260 :A 280 was 1.5 or greater. RNA samples were treated with DNaseI (Ambion) for 30 min at 378C. The RNA was then extracted and puri®ed by serial extractions with equal volumes of phenol, phenol : chloroform (25:24), and chloroform : isoamyl alcohol : butanol (96:4:25). The RNA was then treated with DNaseI again and extracted as described. RNA was then precipitated, washed, dried and resuspended in an appropriate volume of DEPC-treated water. The quality and purity of the RNA was assessed by determining the A 260 :A 280 ratio (typically 1.5 or greater) and by performing PCR with b-actin primers to ensure that there was no contaminating genomic DNA present. 2 mg of RNA was reverse transcribed with 250 ng (or 5 mmol) of the appropriate primer (anchored, random hexamer, or speci®c) by the reverse transcriptase SuperScript II (Gibco-BRL) according to the manufacturer's directions. 1/10 of the reaction was routinely used for PCR for the messages of interest.
Dierential display PCR, cloning, and sequencing of clones
Dierential display was performed as described earlier (Liang and Pardee, 1992; Zhang and Medina, 1993) . RNA samples were treated with DNase twice before reverse transcription and PCR was employed to ensure that no contaminating genomic DNA was present. Reactions were performed in triplicate to decrease the number of potential false positives. 100 ml reactions contained 2.5 units Taq (Promega), 250 pmol reverse (anchored) primer, 50 pmol forward (arbitrary) primer, 20 mM each dNTP, 1 mM MgCl 2 , 5 mCi [a-
35 S]dATP (1000 ± 5000 Ci/mmol, Amersham), and 16PCR buer. Samples were cycled as follows: 5 min at 948C followed by 40 cycles of 948C for 30 s, 35 ± 408C for 2 min and 728C for 30 s, followed by a 5 min dwell at 728C. Samples were run on 6.5% acrylamide sequencing gels. The primer sequences used were T 11 AG and GATACTGCAC. Bands unique to either EL12 or TM12 were cut out of the dried gel using a sterile razor blade. Gel slices were rehydrated in 40 ml sterile distilled water, and the DNA was eluted by boiling the samples brie¯y. PCR products were subcloned into the pGEM-T vector (Promega) following the manufacturer's instructions. DNA sequence was obtained by submitting transformant plasmid DNA for automated¯uorescent sequencing (Applied Biosystems and the Institute for Molecular Genetics, Baylor College of Medicine, Houston, TX). For each sequencing 20 mg of plasmid DNA was submitted at 1.0 mg/ml. Standard universal and reverse primers were used.
Riboprobe synthesis and RNase protection assay
Plasmids carrying the k-1 clone, a cDNA probe for p96, or a cDNA probe for p67 were linearized and treated with Proteinase K (Promega). At least 1 mg of linearized plasmid DNA was extracted, precipitated, dried and resuspended in sterile distilled water to a ®nal concentration of 500 mg/ml. 500 mg of DNA were routinely transcribed according to the manufacturer's directions (Promega), except for the following: the DNA template was removed by treatment with DNaseI (Ambion) for 30 min at 378C. The DNaseI was inactivated by incubation at 908C for 3 ± 5 min. All riboprobes were gel-puri®ed on 5% acrylamide gels. Elution was allowed to proceed overnight at 378C, according to the manufacturer's instructions (Ambion). The RPA II kit (Ambion) was used for RNase protection assays. 5610 4 c.p.m. of each probe of interest, 5610 3 c.p.m. of control probe (b-actin or 18S RNA), and 20 mg target RNA were routinely used. Protected fragments were run on 5% acrylamide gels, dried, and exposed to ®lm.
Protein isolation, polyacrylamide gel electrophoresis, and immunoblotting
Tissue and tumor samples were homogenized in a Kontes tube in cell lysis buer (50 mM HEPES, pH 7.4; 150 mM NaCl; 1.5 mM MgCl 2 ; 10% glycerol; 1% Triton X-100; 1 mM EGTA, pH 7.4; 10 mg/ml leupeptin; 10 mg/ml aprotinin; 1 mM phenylmethylsulfonyl¯uoride; 0.2 mM Na 3 VO 4 ; 10 mM Na 4 P 2 O 7 ; 100 mM NaF). Following a 15 min incubation on ice, the lysate was sonicated four times of three pulses each, and then centrifuged at 13 200 r.p.m. 48C for 30 min. The cleared lysate supernatant was transferred to a fresh 1.5 ml microcentrifuge tube, and quantitation of the amount of protein present was performed using the BCA Protein Assay Reagent kit (Pierce). 500 mg of sample were denatured in 16SDS solubilization buer (2% SDS; 0.1 M Tris-HCl, pH 6.8; 10% glycerol; 0.0001% bromophenol blue; 3.5% bmercaptoethanol) by boiling for 5 min, then loaded onto a 7.5% acrylamide gel. After electrophoresis at 20 ± 25 mamps, the gel was electrophoretically transferred to a nitrocellulose membrane (Schleicher and Schuell) in prechilled transfer buer (25 mM Tris base; 192 mM glycine; 20% methanol; 0.125% SDS) for 15 min at 1 25 volts, then 2.5 h at 1 amp. The membrane was blocked in a solution of 5% nonfat dried milk in 16TBS for 1 h. Incubation in anti-p96 monoclonal primary antibody (1:2500; Transduction Laboratories) took place at 48C for 8 ± 16 h. The membrane was washed three times in 5% milk with 0.1% Tween-20 in 16TBS for 5 min each. Incubation with the secondary antibody occurred at RT for at least 1.5 h in milk solution. Following the ®nal wash for 5 min each ®ve times in 5% milk with 0.1% Tween-20 in 16TBS, the membrane was rinsed in 16TBS in preparation for detection with the ECL kit (Amersham).
